🧸 j . . 🛓

Attorney Docket No.: 4318.224-USEST AVAILABLE COPY

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No.: 09/902.188

Group Art Unit: 1751

Filed: July 10, 2001

**Examiner: Prouty** 

For: Amylase Variants

### RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, DC 20231

Sir:

This paper is filed in response to the Office Action mailed March 25, 2003 that made a restriction requirement. Applicants were requested to elect one of two designated groups.

In response to this requirement, Applicants hereby elect the invention of Group I, Claims 68-77, 86-95, 104-113 and 122-131, drawn to alpha-amylase mutants and compositions theroof. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: April 23, 2003

geon I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212) 840-0097

PAGE 03/03

MODOSAMES NA

2128400221 04/54/5003 00:44





# **FAX COVER SHEET**

No. of pages incl. this: 3		OFFICIAL
Telefax no.:	(703)308-4242	
To:	<b>Examiner: Prouty</b>	FAX RECEIVED  APR 2 5 2003  GROUP 1600
From:	Jason Garbeli	
Date:	April 24, 2003	
Message:		
Response to Restri	ction Requirement	

**Novozymes North America, Inc.**Patents-US

500 Fifth Avenue, Suite 1600 New York, NY 10110 Telephone: (212) 840-0097, ext. 15 Telefax: (212) 840-0221

email: JGar@novozymes.com internet: www.novozymes.com



Attorney Docket No.: 4318.224-US

PATENT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No. 09/902,188

Group Art Unit: 1754 16052

Filed: July 10, 2001

Examiner: Prouty

For: Amylase Variants

#### **CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

was sent to the United States Patent Office by telefax to the attention of Examiner Prouty, fax number 703-308-4242.

Respectfully submitted.

Date: April 24, 2003

Julié Tabarovsky

Novozymes North America, Inc.

500 Fifth Avenue, Suite 1600

New York, NY 10110

(212) 840-0097